Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Post by Ciaoon Feb 16, 2024 1:23pm
175 Views
Post# 35884544

AEZS approached CZO

AEZS approached CZOTalk about negotiating from a position of strength to weakness (p. 25 of info circular)

In October 2022, the Board became aware that Aeterna Zentaris was conducting a strategic review of its operations and of the opportunity to combine Ceapro’s business with the business of Aeterna Zentaris. After analyzing the merits of this opportunity internally, in early November 2022, the Board decided to express to Aeterna Zentaris its interest in pursuing a combination of their two businesses. However, after initial exploratory discussions, Aeterna Zentaris decided not to advance Ceapro to its short-list of companies with whom it would pursue negotiations towards a potential transaction. Subsequently, in December 2022, Aeterna Zentaris informed Ceapro that it was interested in re-engaging with Ceapro regarding a potential business combination transaction. Ceapro and Aeterna Zentaris then entered into a confidentiality agreement effective December 15, 2022 and began discussions in order to explore the potential terms of such a transaction.

I wonder if it was Gilles that initated this back in Oct. 2022?

(i) that the proposed strategic transaction would be structured as an all-stock merger acquisition by Ceapro of Aeterna Zentaris, with the shareholders of Aeterna Zentaris owning between 41-45% and the shareholders of Ceapro owning between 55-59%

Yes, this is essentially a takeover of CEAPRO at liquidation valuations, but instead of CEAPRO having a larger interest in the new entity, we could end up with a 50 / 50 deal. Putting lipstick on a pig and calling it a merger of equals, how pathetic.
<< Previous
Bullboard Posts
Next >>